폴라리스AI파마
Financials
Valuation Metrics
폴라리스AI파마's Market Cap is ₩704B. At end of 2025 it was ₩828B. Ranked #1486 of 2,436 in KR market (top 61%), #850 of 1,649 on KOSDAQ (top 52%), #163 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 70%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 70.40B KRW | KR#1,486/2,436 Sec#163/234 |
| Revenue | 56.48B KRW | KR#1,713/2,436 Sec#117/234 |
| Net Income | 8.83B KRW | KR#941/2,436 Sec#62/234 |
| Total Assets | 198.55B KRW | KR#1,287/2,436 Sec#98/234 |
| Net Assets | 141.28B KRW | KR#1,145/2,436 Sec#86/234 |
| Employees | 164 | KR#1,239/2,436 Sec#102/234 |
| Value | ||
| P/E | 7.97x | KR#553/2,436 Sec#25/234 |
| P/B | 0.50x | KR#792/2,436 Sec#33/234 |
| PEG | 0.03x | KR#184/2,436 Sec#9/234 |
| P/S | 1.25x | KR#1,542/2,436 Sec#89/234 |
| EV/EBITDA | 28.35x | KR#1,161/2,436 Sec#74/234 |
| FCF Yield | 11.76% | KR#556/2,436 Sec#19/234 |
| Profitability | ||
| ROE | 6.25% | KR#872/2,436 Sec#68/234 |
| ROA | 4.45% | KR#716/2,436 Sec#58/234 |
| Op. Margin | 5.42% | KR#875/2,436 Sec#71/234 |
| Revenue Growth | 7.32% | KR#1,057/2,436 Sec#97/234 |
| Earnings Growth | 270.91% | KR#190/2,436 Sec#12/234 |
| Financial Health | ||
| Debt Ratio | 140.53% | KR#1,051/2,436 Sec#121/234 |
| Total Debt | 47.14B KRW | KR#1,005/2,436 Sec#69/234 |
| FCF | 8.28B KRW | KR#762/2,436 Sec#43/234 |
| Cash | 30.82B KRW | KR#994/2,436 Sec#65/234 |
| Current Ratio | 4.11x | KR#395/2,436 Sec#69/234 |
| Net Debt/EBITDA | 5.33x | KR#1,105/2,436 Sec#84/234 |
| Dividend | ||
| Div. Yield | 1.72% | KR#966/2,436 Sec#51/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -23.08% | KR#1,378/2,436 Sec#112/234 |
| 1M Return | 7.07% | KR#405/2,436 Sec#30/234 |
| From 52W High | -48.04% | KR#1,107/2,436 Sec#91/234 |
| 1Y MDD | -51.79% | KR#999/2,436 Sec#82/234 |
| Trading | ||
| Volume | 44,110 shares | KR#1,636/2,436 Sec#152/234 |
| Foreign Own. | 1.02% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 654 KRW | KR#803/2,436 Sec#59/234 |
| BPS | 10,636 KRW | KR#909/2,436 Sec#64/234 |
Company Info
Established in 1999 and listed on KOSDAQ in 2004, the company became an affiliate of Polaris Group in 2024, benefiting from group human resources and AI technology collaboration. It produces over 60 types of active pharmaceutical ingredients (APIs) using organic synthesis and chiral technologies, conducting both API and CDMO businesses. The company aims to expand its CDMO services to include development and production, adapting to AI technology shifts in the pharmaceutical and bio industries, including AI new drugs. Polaris AI Pharma was founded in 1998 and is headquartered in Hwaseong-si, Gyeonggi-do.